Control of resection margins after neoadjuvant systemic therapy in breast-conserving surgery in breast cancer patients

Abstract

BACKGROUND: Surgical treatment of breast cancer plays a major role in the combined and complex treatment of patients. The “purity” of the examined edges of the resected breast tissue is the main indicator of the reliability of the breast-conserving surgery and one of the main factors in the development of local recurrence. Neoadjuvant (preoperative) systemic therapy allows evaluating the effectiveness of therapy in vivo and reducing the size of the initial formation, both in locally advanced and resectable forms of breast cancer. The main advantage of this treatment is the ability for surgeons to perform breast-conserving surgery to improve patients quality of life and aesthetic outcomes without compromising disease-free and overall survival.

AIM: To study the clinical and pathological characteristics and analyze of the breast-conserving surgery in patients with breast cancer after neoadjuvant chemotherapy.

MATERIALS AND METHODS: 156 performed breast-conserving surgery after neoadjuvant chemotherapy were analyzed. Breast-conserving resection implied radical removal of the residual tumor node within healthy breast tissues with the achievement of negative resection margins. If pathologists detected stained invasive cells/cancer in situ in a formalin-fixed preparation, a second surgical intervention was performed.

RESULTS: Of the 156 studied anatomical preparations after breast-conserving surgery, a positive margin was found in 4 (2.56%) cases. In 4 patients, positive margin was represented by ductal carcinoma in situ. According to the results of trephine biopsy, no intraductal component was found before neoadjuvant chemotherapy. The greatest length of the ductal carcinoma in situ section is 2.2 mm. In 3 cases, the distance to the stained resection margin of the micropreparation was 1 mm. As a result of repeated pathomorphological examination of pre-cut margins after surgical intervention, cancer in situ was not found.

CONCLUSIONS: The ongoing neoadjuvant systemic therapy for breast cancer with a partial or complete response of the tumor increases the percentage of breast-conserving surgery performed in patients who initially belong to the group of radical mastectomy, but who want to save breast tissue.

Keywords

breast-conserving surgery / breast cancer / resection margins / neoadjuvant chemotherapy

References

[1] Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–1241. DOI: 10.1056/NEJMoa022152

[2] Fisher B., Anderson S., Bryant J. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer // N. Engl. J. Med. 2002. Vol. 347, No. 16. P. 1233–1241. DOI: 10.1056/NEJMoa022152

[3] Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–1232. DOI: 10.1056/NEJMoa020989

[4] Veronesi U., Cascinelli N., Mariani L. et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer // N. Engl. J. Med. 2002. Vol. 347, No. 16. P. 1227–1232. DOI: 10.1056/NEJMoa020989

[5] Zikiryakhodzhaev AD, Ermoshchenkova MV, Volchenko NN, et al. Resection margin status during organ-sparing surgery for breast cancer. P.A. Herzen Journal of Oncology. 2015;4(6):65–73. (In Russ.) DOI: 10.17116/onkolog20154665-73

[6] Зикиряходжаев А.Д., Ермощенкова М.В. Состояние краев резекции при органосохраняющих операциях по поводу рака молочной железы // Онкология. Журнал им. П.А. Герцена. 2015. № 6(4). С. 65–73. DOI: 10.17116/onkolog20154665-73

[7] Semiglazov VF, Semiglazov VV, Nikolaev KS, et al. The control of surgical margins for organ-preserving treatment of breast cancer. Cancer Surgery. 2014;(1):58–63. (In Russ.)

[8] Семиглазов В.Ф., Семиглазов В.В., Николаев К.С. и др. Контроль хирургических краев резекции при органосохраняющем лечении рака молочной железы // Онкохирургия. 2014. № 1. С. 58–63.

[9] Boughey JC, Peintinger F, Meric-Bernstam F, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006;244(3):464–470. DOI: 10.1097/01.sla.0000234897.38950.5c

[10] Boughey J.C., Peintinger F., Meric-Bernstam F. et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer // Ann. Surg. 2006. Vol. 244, No. 3. P. 464–470. DOI: 10.1097/01.sla.0000234897.38950.5c

[11] Volders JH, Negenborn VL, Spronk PE, et al. Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes. Breast Cancer Res Treat. 2018;168(1):1–12. DOI: 10.1007/s10549-017-4598-5

[12] Volders J.H., Negenborn V.L., Spronk P.E. et al. Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes // Breast Cancer Res. Treat. 2018. Vol. 168, No. 1. P. 1–12. DOI: 10.1007/s10549-017-4598-5

[13] Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700–1712. DOI: 10.1093/annonc/mdx308

[14] Curigliano G., Burstein H.J., Winer E.P. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 // Ann. Oncol. 2017. Vol. 28, No. 8. P. 1700–1712. DOI: 10.1093/annonc/mdx308

[15] Volders JH, Haloua MH, Krekel NM, et al. Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes: A nationwide pathology study. Eur J Surg Oncol. 2016;42(7):986–993. DOI: 10.1016/j.ejso.2016.02.252

[16] Volders J.H., Haloua M.H., Krekel N.M. et al. Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes: A nationwide pathology study // Eur. J. Surg. Oncol. 2016. Vol. 42, No. 7. P. 986–993. DOI: 10.1016/j.ejso.2016.02.252

[17] Wang SY, Chu H, Shamliyan T, et al. Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst. 2012;104(7):507–516. DOI: 10.1093/jnci/djs142

[18] Wang S.Y., Chu H., Shamliyan T. et al. Network meta-analysis of margin threshold for women with ductal carcinoma in situ // J. Natl. Cancer Inst. 2012. Vol. 104, No. 7. P. 507–516. DOI: 10.1093/jnci/djs142

[19] Gobardhan PD, de Wall LL, van der Laan L, et al. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy. Ann Oncol. 2013;24(3):668–673. DOI: 10.1093/annonc/mds475

[20] Gobardhan P.D., de Wall L.L., van der Laan L. et al. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy // Ann. Oncol. 2013. Vol. 24, No. 3. P. 668–673. DOI: 10.1093/annonc/mds475

[21] Rubio IT, Esgueva-Colmenarejo A, Espinosa-Bravo M, et al. Intraoperative ultrasound-guided lumpectomy versus mammographic wire localization for breast cancer patients after neoadjuvant treatment. Ann Surg Oncol. 2016;23(1):38–43. DOI: 10.1245/s10434-015-4935-z

[22] Rubio I.T., Esgueva-Colmenarejo A., Espinosa-Bravo M. et al. Intraoperative ultrasound-guided lumpectomy versus mammographic wire localization for breast cancer patients after neoadjuvant treatment // Ann. Surg. Oncol. 2016. Vol. 23, No. 1. P. 38–43. DOI: 10.1245/s10434-015-4935-z

[23] Haque W, Verma V, Hatch S, et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170(3):559–567. DOI: 10.1007/s10549-018-4801-3

[24] Haque W., Verma V., Hatch S. et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy // Breast Cancer Res. Treat. 2018. Vol. 170, No. 3. P. 559–567. DOI: 10.1007/s10549-018-4801-3

[25] Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004;22(12):2303–2312. DOI: 10.1200/JCO.2004.09.062

[26] Chen A.M., Meric-Bernstam F., Hunt K.K. et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience // J. Clin. Oncol. 2004. Vol. 22, No. 12. P. 2303–2312. DOI: 10.1200/JCO.2004.09.062

[27] Brouwer de Koning SG, Vrancken Peeters MTFD, Jóźwiak K, et al. Tumor resection margin definitions in breast-conserving surgery: Systematic review and meta-analysis of the current literature. Clin Breast Cancer. 2018;18(4):e595–e600. DOI: 10.1016/j.clbc.2018.04.004

[28] Brouwer de Koning S.G., Vrancken Peeters M.T.F.D., Jóźwiak K. et al. Tumor resection margin definitions in breast-conserving surgery: Systematic review and meta-analysis of the current literature // Clin. Breast Cancer. 2018. Vol. 18, No. 4. P. e595–e600. DOI: 10.1016/j.clbc.2018.04.004

[29] Muttalib M, Tisdall M, Scawn R, et al. Intra-operative specimen analysis using faxitron microradiography for excision of mammographically suspicious, non-palpable breast lesions. Breast. 2004;13(4):307–315. DOI: 10.1016/j.breast.2004.02.005

[30] Muttalib M., Tisdall M., Scawn R. et al. Intra-operative specimen analysis using faxitron microradiography for excision of mammographically suspicious, non-palpable breast lesions // Breast. 2004. Vol. 13, No. 4. P. 307–315. DOI: 10.1016/j.breast.2004.02.005

RIGHTS & PERMISSIONS

Eco-Vector